Abiopharma

🔍 Gleason Scott (Executive)

Company: SERA PROGNOSTICS, INC. (SERA)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 117,924 shares of Class A Common Stock (Direct)
  Date: 2026-08-31 | Code: A | equity_swap_involved: false | shares_owned_after: 117,924.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 169,624 shares of Stock Option (right to buy) at $2.12 per share (Derivative)
  Date: 2026-08-31 | Code: A | Expires: 2036-08-31 | equity_swap_involved: false | shares_owned_after: 169,624.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over four years as follows: 25% of the original grant amount vests on the first anniversary of the vesting commencement date, which is September 10, 2026, and 1/12 of the remaining amount vests in quarterly installments for three years thereafter, subject to the Reporting Person continuing to provide services to the issuer.
• F2: These stock options vest over four years as follows: 25% of the original grant amount vests on the first anniversary of the vesting commencement date, which is September 10, 2026, and 1/36 of the remaining amount vests in monthly installments for three years thereafter, subject to the Reporting Person continuing to provide services to the issuer.